🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to health experts.

An International Public Health Issue

The sexually transmitted infection are escalating globally, with figures suggesting in excess of 82 million new cases annually. Notably increased rates are seen in Africa and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the reality of growing infection rates, increasing antimicrobial resistance and the very limited available drugs at this time.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance found that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts hope that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is employed against UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization signifies a significant shift in the therapy of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Outcomes and Worldwide Availability

According to data detailed in a major medical journal, zoliflodacin cured over nine in ten of uncomplicated infections. This places it at an comparable level with the typical regimen, which combines a dual-drug approach. The research included hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the authority to make available and distribute the drug in many developing nations.

Doctors directly involved have expressed positive views. Having a one-pill regimen like this is hailed as a "critical tool" for public health efforts. This is considered vital to alleviate the strain of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea worldwide.